Article
Source: Campus Sanofi

T1 Edition Junior Study

Author : Sanofi

Editorial Team

Edition Junior

Download this clinical summary to read about the benefits of Toujeo® Insulin Glargine 300U/ml in children and adolescents from the age of 6 years in this randomised trial. Edition Junior was a 6 month long, open-label, double arm, parallel group, non-inferiority study in 463 children with T1DM. The aim of the study was to demonstrate non-inferiority of Toujeo^® vs insulin glargine 100 U/mL from baseline to Week 26.

Download

See More From Science

Toujeo

Toujeo^® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

More About Toujeo

Patient Materials

Find resources and support for your patients who have been prescribed Toujeo^®. This section will help you to help your patients understand the basis of living and staying well with diabetes and how to have a a positive start and experience with Toujeo^®.

Access Patient Materials